新辅助化疗联合卡瑞利珠单抗治疗局部晚期宫颈癌(NACI研究):多中心、单臂、2期试验
这项在中国八家三级医院开展的单臂2期试验纳入85例局部晚期宫颈癌患者,给予新辅助化疗联合卡瑞利珠单抗。客观缓解率达98%(95%CI 92-100),其中完全缓解19%、部分缓解79%。最常见3-4级治疗相关不良事件为淋巴细胞减少(25%)、中性粒细胞减少(12%)和白细胞减少(8%),未发生严重不良事件或治疗相关死亡。
要点
- 新辅助化疗联合卡瑞利珠单抗在局部晚期宫颈癌中客观缓解率达98%(95%CI 92-100)。
- 完全缓解16例(19%),部分缓解67例(79%)。
- 最常见3-4级治疗相关不良事件为淋巴细胞减少25%、中性粒细胞减少12%、白细胞减少8%。
核心结论
- 新辅助化疗联合卡瑞利珠单抗在局部晚期宫颈癌中显示出有前景的抗肿瘤活性和可控的不良事件特征。
- 新辅助化疗联合卡瑞利珠单抗序贯根治性手术有望成为局部晚期宫颈癌的新型治疗策略。
研究设计与样本
- 单臂2期试验,在中国八家三级医院开展。
- 纳入85例年龄18-70岁、未经治疗的宫颈癌患者(IB3、IIA2或IIB/IIIC1r期,肿瘤直径≥4 cm,国际妇产科联盟2018分期),ECOG体能状态评分0或1。
- 治疗方案:先进行1个周期双药化疗引导(顺铂75-80 mg/m2静脉注射+白蛋白结合型紫杉醇260 mg/m2静脉注射),随后2个周期化疗(第1天顺铂+白蛋白结合型紫杉醇)联合卡瑞利珠单抗(200 mg静脉注射,第2天),周期间隔3周。
- 疾病稳定或进展的患者接受同步放化疗,完全缓解或部分缓解的患者接受根治性手术。
- 主要终点为独立中心审查者根据实体瘤疗效评价标准1.1版评估的客观缓解率。
主要发现
- 2020年12月1日至2023年2月10日期间入组85例患者,全部接受至少一剂卡瑞利珠单抗。
- 中位年龄51岁(IQR 46-57),未收集种族或民族数据。
- 数据截止2023年4月30日,中位随访11.0个月(IQR 6.0-14.5)。
- 83例(98% [95%CI 92-100])患者达到客观缓解,其中16例(19%)完全缓解,67例(79%)部分缓解。
- 新辅助化疗-免疫治疗期间最常见的3-4级治疗相关不良事件为淋巴细胞减少(21/85,25%)、中性粒细胞减少(10/85,12%)和白细胞减少(7/85,8%)。
关键数值与推荐
- 客观缓解率98%(95%CI 92-100),完全缓解19%,部分缓解79%。
- 3-4级治疗相关不良事件:淋巴细胞减少25%(21/85)、中性粒细胞减少12%(10/85)、白细胞减少8%(7/85)。
临床怎么用
- 新辅助化疗联合卡瑞利珠单抗序贯根治性手术在局部晚期宫颈癌中显示出有前景的抗肿瘤活性和可控的不良事件特征,作者认为该联合方案有望成为新型治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Locally advanced cervical cancer constitutes around 37% of cervical cancer cases globally and has a poor prognosis due to limited therapeutic options. Immune checkpoint inhibitors in the neoadjuvant setting could address these challenges. We aimed to investigate the efficacy and safety of neoadjuvant chemo-immunotherapy for locally advanced cervical cancer. METHODS: In this single-arm, phase 2 trial, which was done across eight tertiary hospitals in China, we enrolled patients aged 18-70 years with untreated cervical cancer (IB3, IIA2, or IIB/IIIC1r with a tumour diameter ≥4 cm [International Federation of Gynecology and Obstetrics, 2018]) and an Eastern Cooperative Oncology Group performance status of 0 or 1. Eligible patients underwent one cycle of priming doublet chemotherapy (75-80 mg/m2 cisplatin, intravenously, plus 260 mg/m2 nab-paclitaxel, intravenously), followed by two cycles of a combination of chemotherapy (cisplatin plus nab-paclitaxel) on day 1 with camrelizumab (200 mg, intravenously) on day 2, with a 3-week interval between treatment cycles. Patients with stable disease or progressive disease received concurrent chemoradiotherapy, and patients with a complete response or partial response proceeded to radical surgery. The primary endpoint was the objective response rate, by independent central reviewer according to Response Evaluation Criteria in Solid Tumours, version 1.1. Activity and safety were analysed in patients who received at least one dose of camrelizumab. This study is registered with ClinicalTrials.gov, NCT04516616, and is ongoing. FINDINGS: Between Dec 1, 2020, and Feb 10, 2023, 85 patients were enrolled and all received at least one dose of camrelizumab. Median age was 51 years (IQR 46-57) and no data on race or ethnicity were collected. At data cutoff (April 30, 2023), median follow-up was 11·0 months (IQR 6·0-14·5). An objective response was noted in 83 (98% [95% CI 92-100]) patients, including 16 (19%) patients who had a complete response and 67 (79%) who had a partial response. The most common grade 3-4 treatment-related adverse events during neoadjuvant chemo-immunotherapy were lymphopenia (21 [25%] of 85), neutropenia (ten [12%]), and leukopenia (seven [8%]). No serious adverse events or treatment-related deaths occurred. INTERPRETATION: Neoadjuvant chemo-immunotherapy showed promising antitumour activity and a manageable adverse event profile in patients with locally advanced cervical cancer. The combination of neoadjuvant chemo-immunotherapy with radical surgery holds potential as a novel therapeutic approach for locally advanced cervical cancer. FUNDING: National Key Technology Research and Development Program of China and the National Clinical Research Center of Obstetrics and Gynecology.
引用
- Li K, Chen J, Hu Y, et al. Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2023. PMID: 38048802. doi:10.1016/S1470-2045(23)00531-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。